Congress in Spain were a major feature of research news last week, including those from Pfizer on it ponsegromab in cancer ...

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's ...

GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, Germany/BOSTON, USA – September 12, 2024 – CureVac N.V ...

Before the recalls, Zantac was sold by GSK, US pharma giant Pfizer, French drug company Sanofi and Boehringer Ingelheim, based in Germany. GSK said in a press release on Tuesday: "GSK welcomes ...

TÜBINGEN, GERMANY and BOSTON, MA - GlaxoSmithKline (NYSE:GSK) has reported encouraging Phase 2 results for its mRNA-based seasonal influenza vaccine, which utilizes technology from ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on ...

GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September ...

GSK has upgraded its longstanding alliance with ... Merck eyes deal with Afrigen Biologics In other mRNA vaccine news today, Germany’s Merck KGaA revealed that it has signed a non-binding ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Patients with advanced SSC of the anal canal have a marked survival benefit when immunotherapy is added to standard-of-care ...